Vivos Therapeutics (VVOS) Registration Filing summary

Company overview and business model

• Operates as a medical technology and services company offering proprietary oral appliances and therapies for non-surgical treatment of maxillofacial abnormalities and sleep disorders, especially obstructive sleep apnea (OSA).

• Transitioned from a dentist-focused legacy model to a new strategy centered on alliances and acquisitions of sleep centers, enabling direct patient access and profit-sharing with providers.

• Acquired The Sleep Center of Nevada in June 2025, integrating operations to expand diagnostic and treatment services, and is developing a management model for collaborations with sleep centers unwilling to sell.

• The Vivos Method, its flagship treatment, is FDA-cleared and supported by clinical data, offering a limited treatment duration and potential for lasting results.

Financial performance and metrics

• As of September 4, 2025, the aggregate market value of common stock held by non-affiliates was approximately $40.9 million, with 5,881,977 shares outstanding at a $6.95 per share price.

• Initial SCN integration generated a small amount of revenue in Q2 2025, with plans to increase revenue in the second half of 2025 and into 2026.

• Each Sleep Optimization (SO) team at SCN is estimated to potentially generate over $500,000 in monthly collections with contribution margins above 50%.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including sales and marketing, R&D, staff and software development, and potential acquisitions of complementary businesses or assets.

• No definitive agreements for acquisitions are in place as of the filing date.